Introduction {#s1}
============

Diabetic nephropathy (DN) remains the most important cause of end-stage renal disease (ESRD) in North America and Europe and also one of the major causes of mortality in type 2 diabetes. The 2011 U.S. Renal Data System showed that DN accounted for 44.5% of all cases of ESRD in the U.S. in 2009 ([@B1]). DN is also an important risk factor for the development of future cardiovascular disease. Unfortunately, the initiation of early DN is clinically silent for many years, and during this time, renal parenchymal damage progresses ([@B2]). Furthermore, early markers of DN prior to the loss of renal function, such as hyperfiltration (glomerular filtration rate \[GFR\] ≥135 mL/min/1.73 m^2^) and albuminuria within the normal range, can manifest in adolescents with type 2 diabetes and are also associated with early cardiovascular abnormalities ([@B3],[@B4]). In fact, adolescents with type 2 diabetes have a twofold increased risk of microalbuminuria compared with youth with type 1 diabetes ([@B5]--[@B7]). In addition to early renal disease being a determinant of future cardiovascular risk, insulin sensitivity is associated with renal health in adults with and without type 2 diabetes ([@B8],[@B9]). Moreover, prediabetic conditions are associated with early preclinical manifestations of kidney dysfunction, including hyperfiltration, in adults ([@B10]). However, limited data exist in adolescents with type 2 diabetes.

Accordingly, our aim was to describe the prevalence of hyperfiltration and albuminuria in a contemporary adolescent cohort of patients with type 2 diabetes. Moreover, we sought to investigate the associations among measured insulin sensitivity, estimated GFR (eGFR), and albumin-creatinine ratio (ACR). In light of associations between insulin insensitivity and early DN in adults, we hypothesized that greater insulin sensitivity would be associated with renal health, reflected by eGFR and ACR within normal ranges, in adolescents with type 2 diabetes.

Research Design and Methods {#s2}
===========================

Participants {#s3}
------------

A total of 94 pubertal adolescents between the ages of 12 and 19 years were recruited for a study of diabetes and insulin resistance in youth and had insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp, as well as data available to calculate ACR and eGFR by creatinine and cystatin C. Of the 94 adolescents, 46 were diagnosed with type 2 diabetes, 29 with obesity (BMI \>95th percentile) but no diabetes, and 19 were normal weight controls (BMI \>5th percentile and \<85th percentile). Family history of diabetes was similar in obese and type 2 diabetic participants, but negative in control participants. Obese participants were chosen to have similar BMI percentile and fat mass as participants with type 2 diabetes. All three subject groups were chosen to be of similar age, level of physical activity, and sex distribution. The study was approved by the University of Colorado Denver institutional review board, and appropriate consent and assent were obtained.

Height and weight were measured for determination of BMI. BMI z-score was calculated using BMI, sex, and age. Absence of diabetes was confirmed in the nondiabetic groups by a 2-h, 75-g oral glucose tolerance test. Type 2 diabetes was defined by American Diabetes Association's criteria and the absence of glutamic acid decarboxylase, islet cell or insulin autoantibodies, insulin requirement, or secondary causes of diabetes, as previously described ([@B11]). Inclusion criteria included pubertal status (Tanner stage \>1) and sedentary status (\<3 h of exercise/week) to minimize training effects. Exclusions included body weight \>300 pounds, blood pressure \>140/90 mmHg at rest or \>190/100 mmHg during exercise, hemoglobin \<9 mg/dL, serum creatinine \>1.5 mg/dL, smoking, antihypertensive drugs, pregnancy, breastfeeding, ≥3 h of physical activity per week, or plans to alter exercise or diet during the study. For participants with type 2 diabetes, additional exclusion criteria included HbA~1c~ ≥12%, medications known to affect insulin sensitivity other than metformin (oral or inhaled steroids, thiazolidinediones, and atypical antipsychotics), and other antidiabetes drugs except insulin. For nondiabetic participants, additional exclusions included medications known to affect insulin sensitivity (metformin, oral or inhaled steroids, thiazolidinediones, and atypical antipsychotics), other antidiabetes drugs, and insulin.

Pubertal development was assessed by a single pediatric endocrinologist using the criteria established by Tanner and Marshall for pubic hair and breast development. Testicular volume was measured using an orchidometer.

Laboratory Measures {#s4}
-------------------

For the 3 days prior to admission, participants were asked to refrain from all strenuous physical activity due to the impact on insulin sensitivity and albuminuria. They were also provided with a Pediatric Clinical and Translational Research Center--prepared weight maintenance, 3-day, fixed macronutrient diet to limit impacts of macronutrient variation on insulin sensitivity and renal function, as previously described in detail ([@B11]). Participants were admitted overnight to the Pediatric Clinical and Translational Research Center to ensure fasting. Type 2 diabetic participants (*n*= 22) on insulin were instructed to replace their long-acting insulin (Lantus or Levemir) as needed with intermediate-acting insulin (NPH) and short-acting insulin (Humalog or Novolog) to ensure that their last long-acting insulin injection was at least 24 h prior to admission (36 h prior to the clamp). The evening of admission, all subcutaneous insulin was replaced by an insulin drip. Participants were then maintained overnight on intravenous regular insulin with adjustments by a standard protocol to maintain near euglycemia (goal blood glucose 100--110 mg/dL) until starting the clamp the next morning. Metformin was not taken within 72 h of the clamp to wash out acute effects on insulin sensitivity. No other antidiabetes drugs except insulin were taken per exclusion criteria (see above). Fasting laboratory evaluation included: total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides, glucose, and HbA~1c~ (Diabetes Control and Complications Trial-calibrated); assays were performed by standard methods. Insulin sensitivity (glucose infusion rate \[GIR\]) was calculated from a 3-h hyperinsulinemic-euglycemic clamp (80 mU \* m^−2^ \* min^−1^ insulin) as previously described ([@B11],[@B12]). Serum creatinine and cystatin C were measured from postclamp samples, which were collected after 3 to 4 h of euglycemia, eliminating the effects of acute glycemia on eGFR ([@B13]). Due to the absence of chronic kidney disease and expected normal to elevated GFRs for age, we used the Bouvet equation to estimate GFR (eGFR = 63.2 \* \[serum creatinine/96\]^−0.35^ \* \[serum cystatin C/1.2\]^−0.56^ \* \[weight/45\]^0.30^ \* \[age/14\]^0.40^) ([@B14],[@B15]). This equation has high accuracy when compared with gold-standard measurements in adolescents with eGFR \>90 mL/min/1.73 m^2^ ([@B14]). Hyperfiltration was defined as eGFR ≥135 mL/min/1.73 m^2^ ([@B4],[@B16]). Spot urine was collected upon admission for urinary albumin and creatinine, and ACR was calculated. Albuminuria was defined as microalbuminuria or greater with ACR ≥30 mg/g.

Imaging {#s5}
-------

Body composition (e.g., adiposity) by DEXA was performed by standard methods on a Hologic device (Hologic, Waltham, MA) ([@B17]).

Statistical Analysis {#s6}
--------------------

Analyses were performed in SAS (version 9.3 for Windows; SAS Institute, Cary, NC). Variables were checked for the distributional assumption of normality using normal plots. The distributions of ACR, triglycerides, and insulin dose were skewed. Therefore, natural log transformations were applied. eGFR by Bouvet and ACR were stratified into tertiles. ANOVA with a Tukey-Kramer *P* value adjustment was used for comparison of continuous variables across the three groups (mid, low, and high tertiles), and least square means were calculated for the tertile groups. The χ^2^ test was used to compare categorical variables in the tertile groups.

Univariate and multivariable linear regression models were used to examine the associations between measured insulin sensitivity, HbA~1c~, LDL-C, non--HDL-C, systemic blood pressure (SBP), diastolic blood pressure, natural log of ACR (LnACR), lean mass and fat mass with eGFR by Bouvet, unadjusted and adjusted for Tanner stage, sex, HbA~1c~, BMI percentile, and diabetes duration. Logistic regression models were used to evaluate associations between measured insulin sensitivity with hyperfiltration (eGFR ≥135 mL/min/1.73 m^2^) and albuminuria (ACR ≥30 mg/g), unadjusted and adjusted for Tanner stage, sex, HbA~1c~, BMI percentile, and diabetes duration. Significance was based on an α-level of 0.05.

Results {#s7}
=======

Participant Characteristics {#s8}
---------------------------

[Table 1](#T1){ref-type="table"} shows participant characteristics stratified by group (lean, obese, and type 2 diabetic), and [Table 2](#T2){ref-type="table"} shows measured insulin sensitivity, serum creatinine, serum cystatin C, eGFR, and ACR adjusted for Tanner stage and sex. By design, there were no significant differences across groups either in age or sex distribution or between the type 2 diabetic and obese groups for BMI percentile or percent fat mass ([Table 1](#T1){ref-type="table"}). All groups had more females than males, reflective of the typical pediatric type 2 diabetic population. As expected, HbA~1c~ was elevated in youth with type 2 diabetes and normal in obese and control youth. Average duration of diabetes in youth with type 2 diabetes was 2.0 ± 1.8 years. Of the 13 participants with albuminuria, all of them had a BMI \>85th percentile. Thirty-four percent of participants with type 2 diabetes had albuminuria but only a single participant with obesity had albuminuria. Twenty-four percent of participants with type 2 diabetes exhibited renal hyperfiltration. None of the obese or lean participants exhibited hyperfiltration.

###### 

Participant characteristics for obese, type 2 diabetic, and lean adolescents

  Variable                                                      Obese (*N* = 29)   Type 2 diabetic (*N* = 46)   Lean (*N* = 19)   *P* value
  ------------------------------------------------------------- ------------------ ---------------------------- ----------------- -----------
  Male (%)                                                      34                 29                           41                0.55
  Age (years)                                                   14.8 ± 2.1         15.3 ± 2.3                   14.7 ± 2.1        0.39
  Non-Hispanic white                                            39%                20%                          64%               0.002
  Hispanic                                                      41%                60%                          21%               
  Black                                                         7%                 20%                          15%               
  American-Indian                                               3%                 0%                           0%                
  Asian                                                         7%                 0%                           0%                
  Other                                                         3%                 0%                           0%                
  HbA~1c~ (%)                                                   5.2 ± 0.3          7.9 ± 2.3                    5.1 ± 0.3         \<0.0001
  HbA~1c~ (mmol/mol)                                            33.3 ± 2.1         62.8 ± 22.8                  32.2 ± 2.1        \<0.0001
  Diabetes duration (years)                                     ---                2.0 ± 1.8                    ---               NA
  Height (cm)                                                   165.6 ± 7.8        165.1 ± 9.1                  164.0 ± 7.5       0.78
  Weight (kg)                                                   87.7 ± 23.2        92.7 ± 21.2                  54.7 ± 8.3        \<0.0001
  BMI percentile                                                96 ± 3             97 ± 4                       52 ± 22           \<0.0001
  Fat mass (%)                                                  35.0 ± 13.4        38.4 ± 12.6                  11.9 ± 6.1        \<0.0001
  Waist-to-hip ratio                                            0.90 ± 0.07        0.96 ± 0.09                  0.82 ± 0.07       \<0.0001
  Waist circumference (cm)                                      101.3 ± 21.4       106.4 ± 15.3                 70.1 ± 6.1        \<0.0001
  Total cholesterol (mg/dL)                                     172 ± 35           161 ± 35                     145 ± 24          0.03
  LDL-C (mg/dL)                                                 99 ± 24            87 ± 24                      82 ± 26           0.04
  HDL-C (mg/dL)                                                 42 ± 9             38 ± 11                      46 ± 9            0.02
  Triglycerides[§](#t1n1){ref-type="table-fn"} (mg/dL)          131 ± 2            146 ± 2                      74 ± 1            \<0.0001
  Fasting glucose (mg/dL)                                       88 ± 8             113 ± 29                     89 ± 9            \<0.0001
  Fasting insulin[§](#t1n1){ref-type="table-fn"} (μU/mL)        19 ± 2             31 ± 2                       8 ± 2             \<0.0001
  Steady-state glucose (mg/dL)                                  96 ± 6             98 ± 5                       99 ± 9            0.27
  Steady-state insulin[§](#t1n1){ref-type="table-fn"} (μU/mL)   162 ± 2            148 ± 2                      141 ± 2           0.68
  GIR (mg/kg/min)                                               15.0 ± 6.2         7.6 ± 4.1                    19.9 ± 3.7        \<0.0001
  BUN (mg/dL)                                                   12.9 ± 3.0         11.3 ± 2.1                   12.4 ± 3.9        0.07
  ACR[§](#t1n1){ref-type="table-fn"} (mg/g)                     6.3 ± 2.1          22.6 ± 5.5                   7.6 ± 2.8         0.001
  Serum creatinine (mg/dL)                                      0.72 ± 0.20        0.60 ± 0.16                  0.73 ± 0.15       0.006
  Serum cystatin C (mg/L)                                       0.94 ± 0.12        0.88 ± 0.16                  1.00 ± 0.17       0.02
  eGFR by Bouvet (mL/min/1.73 m^2^)                             103.0 ± 11.3       124.4 ± 24.2                 87.6 ± 14.2       \<0.0001
  SBP (mmHg)                                                    117 ± 9            123 ± 13                     111 ± 8           0.0003
  Diastolic blood pressure (mmHg)                               71 ± 7             72 ± 11                      66 ± 7            0.003
  Tanner 1                                                      0 (0%)             0 (0%)                       0 (0%)            0.0002
  Tanner 2                                                      0 (0%)             1 (2.2%)                     1 (5.3%)          
  Tanner 3                                                      3 (10.3%)          3 (6.5%)                     1 (5.3%)          
  Tanner 4                                                      6 (20.7%)          3 (6.5%)                     10 (52.6%)        
  Tanner 5                                                      20 (69.0%)         39 (84.8%)                   7 (36.8%)         

BUN, blood urea nitrogen; NA, not applicable.

§Geometric means ± SE.

###### 

Tanner and sex-adjusted means for insulin sensitivity and variables of renal health by group for adolescents with type 2 diabetes

  Variable                                                             Obese (*N* = 29)                             Type 2 diabetic (*N* = 46)                        Lean (*N* = 19)
  -------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------- --------------------------------------------
  Steady-state insulin[§](#t2n2){ref-type="table-fn"} (μU/mL)          162 ± 1                                      147 ± 1                                           142 ± 1
  Steady-state glucose (mg/dL)                                         96 ± 1                                       98 ± 1                                            100 ± 2
  GIR (mg/kg/min)                                                      14.9 ± 1.0[\*](#t2n3){ref-type="table-fn"}   7.5 ± 0.8[\*](#t2n3){ref-type="table-fn"}         19.6 ± 1.0[\*](#t2n3){ref-type="table-fn"}
  Serum creatinine (mg/dL)                                             0.75 ± 0.03                                  0.62 ± 0.03[\*\*](#t2n4){ref-type="table-fn"}     0.74 ± 0.03
  Serum cystatin C (mg/L)                                              0.95 ± 0.03                                  0.92 ± 0.02                                       0.99 ± 0.04
  eGFR by Bouvet[^a^](#t2n1){ref-type="table-fn"} (mL/min/1.73 m^2^)   101.0 ± 4.4                                  120.6 ± 3.4[\*\*\*](#t2n5){ref-type="table-fn"}   88.5 ± 5.2
  ACR[§](#t2n2){ref-type="table-fn"} (mg/g)                            6.6 ± 1.3                                    22.2 ± 1.2[\*\*\*](#t2n5){ref-type="table-fn"}    7.5 ± 1.3

Data presented as least square means ± SE.

^a^Not adjusted for age as age is part of Bouvet eGFR equation.

§Geometric means.

\**P* \< 0.01 in all pairwise comparisons.

\*\**P* \< 0.05 compared with obese and lean.

\*\*\**P* \< 0.01 compared with obese and lean.

eGFR and Insulin Sensitivity {#s9}
----------------------------

Insulin sensitivity was lowest in youth with type 2 diabetes and intermediate in obese nondiabetic youth, with no differences in steady-state insulin or glucose values ([Table 2](#T2){ref-type="table"}). In participants with type 2 diabetes, measured insulin sensitivity explained 13.0% (*r* = −0.36; *P* = 0.03) of eGFR, and measured insulin sensitivity was inversely associated with eGFR after adjusting for Tanner stage and sex (β ± SE: −2.23 ± 0.87; *P* = 0.02). HbA~1c~ (*P* = 0.09), LDL-C (*P* = 0.78), SBP (*P* = 0.75), and adiposity (*P* = 0.18) were not significantly associated with eGFR. Stratifying eGFR into tertiles for participants with type 2 diabetes (low \[\<110 mL/min/1.73 m^2^\], middle \[110--128 mL/min/1.73 m^2^\], and high tertiles \[≥129 mL/min/1.73 m^2^\]), participants in the highest tertile had significantly lower measured insulin sensitivity than participants in the middle and low tertiles after adjusting for sex and Tanner stage (*P* \< 0.05; [Fig. 1](#F1){ref-type="fig"}). The difference between the low and middle tertile remained significant after further adjustments for HbA~1c~, BMI, and diabetes duration (*P* = 0.04). No significant differences in HbA~1c~, LDL-C, SBP, or adiposity were observed among the tertiles of eGFR.

![Adjusted means of GIR stratified by tertiles of eGFR in adolescents with type 2 diabetes. Data presented as least square means ± SE adjusted for Tanner and sex (age is part of Bouvet eGFR equation) for adolescents with type 2 diabetes. The difference between low and mid tertiles remained significant after further adjustments for BMI, HbA~1c~, and duration (*P* = 0.04). \**P* \< 0.05 compared with mid and high tertiles; \*\**P* \< 0.05 compared with low tertile.](3033fig1){#F1}

ACR and Insulin Sensitivity {#s10}
---------------------------

In participants with type 2 diabetes, measured insulin sensitivity was not significantly associated with LnACR (β ± SE: −0.10 ± 0.07; *P* = 0.14) in a linear regression model. Similarly, HbA~1c~, LDL-C, SBP, and adiposity were not significantly associated with LnACR in type 2 diabetic participants. Stratifying ACR into tertiles for participants with type 2 diabetes (low \[\<5.6 mg/g\], mid \[5.6--39.3 mg/g\], and high \[≥39.3 mg/g\]), participants in the high ACR tertile had significantly lower insulin sensitivity compared with participants in the low and middle tertile (*P* \< 0.05; [Fig. 2](#F2){ref-type="fig"}). The difference between the high and middle tertile remained significant after further adjustments for Tanner stage, BMI, HbA~1c~, and diabetes duration (*P* = 0.02). In contrast, there were no significant differences in HbA~1c~, LDL-C, SBP, or adiposity between the ACR tertiles.

![Adjusted means of GIR stratified by tertiles of ACR in adolescents with type 2 diabetes. Data presented as least square means ± SE for tertiles of ACR adjusted for age and sex for adolescents with type 2 diabetes. The difference between high and mid tertiles remained significant after further adjustments for Tanner, BMI, HbA~1c~, and duration (*P* = 0.02). \**P* \< 0.05 compared with high tertile; \*\**P* \< 0.05 compared with low or mid tertiles.](3033fig2){#F2}

Hyperfiltration, Albuminuria, and Insulin Sensitivity {#s11}
-----------------------------------------------------

After adjusting for sex, Tanner stage, and diabetes duration, 1-SD increase in measured insulin sensitivity was associated with a lower odds of having albuminuria (odds ratio \[OR\] 0.41 \[95% CI 0.17--0.99\]; *P* = 0.047, per 1 SD \[4.23 mg/kg/min\]) in participants with type 2 diabetes. Further adjustments for HbA~1c~ and BMI attenuated the association (*P* = 0.22). In contrast, 1-SD increase in measured insulin sensitivity was not significantly associated with lower odds of having hyperfiltration (OR 0.54 \[95% CI 0.20--1.47\]; *P* = 0.22, per 1 SD) after adjusting for sex, Tanner stage, and diabetes duration, possibly due to the limited number of observations (hyperfiltration: *n* = 9).

Conclusions {#s12}
===========

Hyperfiltration and albuminuria were present in a significant proportion of adolescents with type 2 diabetes in our cohort, despite their short duration of diabetes. We report lower ACR and eGFR in the normal range in adolescents with higher insulin sensitivity, and insulin sensitivity also appears to be associated with lower odds of having albuminuria. These findings suggest a renoprotective role of insulin sensitivity in adolescents with type 2 diabetes.

Type 2 diabetes remains the leading cause of ESRD in the Western world ([@B18]), and most patients with type 2 diabetes develop some degree of renal dysfunction during their lifetime ([@B8]). The natural history of DN is characterized by a long silent period without overt clinical signs or symptoms of nephropathy. For that reason, a major challenge in preventing DN in type 2 diabetes is the difficulty in accurately identifying high-risk patients with preclinical disease. From our data, conventional risk factors including HbA~1c~, LDL-C, and SBP appear less important than insulin sensitivity in determining renal health in adolescents with type 2 diabetes. Moreover, there was no significant difference in adiposity by using standardized DEXA between the tertiles of ACR and eGFR.

Hyperfiltration and microalbuminuria are early, preclinical phenotypes of DN and are also associated with early cardiovascular abnormalities ([@B3],[@B4]). In the TODAY study with an average follow-up of only 3.9 years ([@B7]), the prevalence of microalbuminuria among youth with type 2 diabetes almost tripled (from 6.3 to 16.6%). In fact, microalbuminuria may precede the development of type 2 diabetes in insulin-resistant obese adolescents ([@B19],[@B20]). Hyperfiltration is thought to be a major contributing factor for DN in type 2 diabetes, reflecting underlying increases in intraglomerular pressure, leading to structural changes over time such as mesangial expansion and glomerular basement membrane thickening ([@B21]). The traditional mechanisms underlying these pathological changes in adolescence are complex and involve growth factors, neurohormonal activation, and changes in renal tubuloglomerular feedback ([@B22]). More recently, insulin resistance has also been implicated in the progression of DN in type 2 diabetes ([@B23],[@B24]). A growing body of data demonstrates that insulin resistance is associated with an elevation of glomerular hydrostatic pressure, causing increased renal vascular permeability and ultimately glomerular hyperfiltration ([@B25]--[@B27]). Another possible mechanistic pathway linking insulin resistance to DN is via effects on overall nonesterified fatty acid exposure and lipotoxicity, leading to the development of microangiopathy ([@B28]). Early signs of DN are present in adolescents with type 2 diabetes, but mechanisms still remain unclear.

The association between insulin resistance and hemodynamic changes in the kidney is increasingly recognized, especially in adults with type 2 diabetes. Parvanova et al. ([@B29]) reported a significant cross-sectional association between measured insulin sensitivity and albuminuria, while De Cosmo et al. ([@B30]) showed that adult males with the highest quartile of HOMA of insulin resistance were more likely to have albuminuria than those in the lowest quartile. Others have demonstrated a longitudinal relationship between insulin resistance by baseline HOMA of insulin resistance and incident microalbuminuria over 5 years ([@B24]). Finally, we have previously demonstrated that reduced estimated insulin sensitivity predicted incident microalbuminuria and rapid GFR decline ([@B31]) and that increased insulin sensitivity predicted regression of albuminuria ([@B32]) in adults with type 1 diabetes. To our knowledge, this report is one of the first to demonstrate an association between measured insulin sensitivity and early renal abnormalities in adolescents with type 2 diabetes. Although evidence from basic and clinical research suggests direct effects of insulin sensitivity on renal health, we cannot rule out the presence of underlying common risk factors being responsible for both worsening insulin sensitivity and renal pathology.

Since insulin sensitivity can be modified by both lifestyle changes (diet and exercise) and drugs such as metformin, improved insulin sensitivity holds promise as a therapeutic target to reduce DN in adolescents with type 2 diabetes. The BARI-2D study ([@B33]) showed no benefit of insulin sensitizing strategy on DN in older adults with coronary artery disease and type 2 diabetes, but with a mean age of 62 years and most participants having both hypertension and hyperlipidemia, this is a very different study population than ours ([@B34]). The renal injury in longstanding nephropathy in older adults with multiple cardiovascular risk factors may also be less responsive to changes in insulin sensitivity than the early alterations in renal function seen in adolescents with type 2 diabetes. Since signs of DN are already present in youth with type 2 diabetes, early interventions may have the greatest effect in preventing further progression of DN.

Our study does have limitations. First, our sample size was limited. However, to minimize the effect of the sample size, we used careful physiological measurements, including direct insulin sensitivity assessments by hyperinsulinemic-euglycemic clamp studies, accepted as the gold-standard method for determining insulin sensitivity. Moreover, we measured adiposity by using standardized DEXA and could therefore evaluate the association between adiposity and DN, and normalized glucose for an extensive period and standardized activity and diet to eliminate the confounding impacts of acute glycemia, exercise, and macronutrient content on renal measures ([@B35]). Although we attempted to remove the effect of acute glycemia on insulin sensitivity and the renal measures as much as possible, we cannot completely rule out the confounding effects of more chronic glucose toxicity. We did adjust for HbA~1c~ in our analyses, but with HbA~1c~ only available at a single time point, we cannot account for the glycemic control over the complete disease duration of our adolescents with type 2 diabetes. Conversely, we previously demonstrated that HbA~1c~ was not associated with insulin sensitivity in adolescents with type 2 diabetes ([@B11]). The groups were also similar for age and activity level and, for participants with type 2 diabetes and obesity, for BMI and percentage fat. Another limitation to the current study included the cross-sectional design that prevents determining causality. Finally, we used an estimate of GFR to assess renal function. However, we used the Bouvet equation, which is state of the art and has been shown to have high accuracy in estimating GFR in children and adolescents with GFR \>90 mL/min/1.73 m^2^ ([@B14]).

With type 2 diabetes being the most common cause of ESRD in the Western world, it is critical to develop a better understanding of the determinants of DN risk and progression to improve outcomes in youth diagnosed with type 2 diabetes. In particular, the onset of type 2 diabetes in adolescence and the high rates of microalbuminuria and hyperfiltration at presentation forecast early renal morbidity and mortality, making youth with type 2 diabetes a vital population to study. In this report, insulin sensitivity, rather than adiposity, blood pressure, lipid, and glycemic control, was associated with renal health in a contemporary cohort of adolescents with type 2 diabetes. Further research is required to further evaluate the role of insulin sensitivity in the pathogenesis of DN in adolescents with type 2 diabetes and response to treatment.
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